mTOR inhibitors (mTORi) (e.g., everolimus) have become the first-line treatment for the management of SEGAs not requiring immediate surgical treatment, with studies showing a strong volume contraction as a result of the treatment and subsequent hydrocephalus prevention, as well as seizure reduction and even improvement of other manifestations of TSC [109,110]. This evidence concerns the gene MTOR and tuberous sclerosis.